Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Talabostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.86 |
| ▸ | DPP7 | Q9UHL4 | 17/20 | 0.86 |
| ▸ | DPP8 | Q6V1X1 | 15/20 | 0.86 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 0.86 |
| ▸ | FAP | Q12884 | 13/20 | 0.86 |
| ▸ | PREP | P48147 | 5/20 | 0.86 |
| ▸ | PITRM1 | Q5JRX3 | 4/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talabostat SCHEMBL23070729 | 1.00 | DPP4 (0.86) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL7417653 | 1.00 | DPP4 (0.86) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL14160935 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL6895250 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL12185345 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL393024 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL14160998 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL4320843 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL21156686 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL14160999 | 0.93 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | claimed |
| EP-4640714-A2 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML Screening, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250213681-A1 | NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION | OAKTREE FUND ADMINISTRATION, LLC | 2025-07-03 | — | — | US | claimed |
| WO-2024227137-A1 | STRUCTURALLY-REINFORCED STABLE THERANOSTIC COPPER RADIOPHARMACEUTICALS TARGETING FIBROBLAST ACTIVATION PROTEIN FOR CANCER DIAGNOSIS AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-31 | — | — | WO | claimed |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2024-08-22 | — | — | US | claimed |
| WO-2024155790-A2 | NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION | ONKOSXCEL THERAPEUTICS, LLC (US) | 2024-07-25 | — | — | WO | claimed |
| CN-116333190-B | Multiple-response prodrug polymer, preparation method and application | 郑州大学 | 2024-05-24 | — | — | CN | claimed |
| WO-2024107832-A2 | TREATMENT REGIMEN FOR TREATING CANCERS | ONKOSXCEL THERAPEUTICS, LLC (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2024097856-A1 | PREDICTIVE BIOMARKERS FOR RESPONSIVENESS TO DPP INHIBITORS IN CANCERS | ONKOSXCEL THERAPEUTICS, LLC (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | claimed |
| US-11564986-B2 | Approach for treatment of cancer via immunomodulation by using talabostat | ONKOSXCEL THERAPEUTICS, LLC (US) | 2023-01-31 | — | — | US | claimed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| WO-2022187241-A1 | COMPOSITIONS AND METHODS FOR TARGETING CARD8 | WASHINGTON UNIVERSITY (US) | 2022-09-09 | — | — | WO | claimed |
| US-20220257759-A1 | TREATMENT OF SARCOMA USING IMMUNOMODULATION | OAKTREE FUND ADMINISTRATION, LLC | 2022-08-18 | — | — | US | claimed |
| WO-2022094237-A1 | ENZYME ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| WO-2022094262-A1 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | AVACTA LIFE SCIENCES LIMITED (GB) | 2022-05-05 | — | — | WO | claimed |
| US-20220089733-A1 | NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION | OAKTREE FUND ADMINISTRATION, LLC | 2022-03-24 | — | — | US | claimed |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2022-02-10 | — | — | US | claimed |
| US-20220025061-A1 | COMBINATION THERAPIES FOR TREATING DISEASE USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST | OAKTREE FUND ADMINISTRATION, LLC | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | DPP4 1257/4885DPP7 1040/4885DPP8 880/4885 |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | DPP4 1257/4885DPP7 1040/4885DPP8 880/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
| US-20220040149-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | DPP4 1257/4885DPP7 1040/4885DPP8 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.